Schroder Investment Management Group trimmed its position in Chemed Co. (NYSE:CHE) by 10.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,582 shares of the company’s stock after selling 412 shares during the quarter. Schroder Investment Management Group’s holdings in Chemed were worth $1,149,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Boston Partners raised its position in Chemed by 2.7% in the 2nd quarter. Boston Partners now owns 160,271 shares of the company’s stock worth $51,577,000 after purchasing an additional 4,186 shares during the period. Summit Trail Advisors LLC raised its position in Chemed by 28,358.4% in the 1st quarter. Summit Trail Advisors LLC now owns 156,521 shares of the company’s stock worth $157,000 after purchasing an additional 155,971 shares during the period. Renaissance Technologies LLC raised its position in Chemed by 92.6% in the 2nd quarter. Renaissance Technologies LLC now owns 137,900 shares of the company’s stock worth $44,378,000 after purchasing an additional 66,300 shares during the period. Principal Financial Group Inc. raised its position in Chemed by 3.7% in the 1st quarter. Principal Financial Group Inc. now owns 133,004 shares of the company’s stock worth $36,291,000 after purchasing an additional 4,689 shares during the period. Finally, Millennium Management LLC purchased a new position in Chemed in the 2nd quarter worth $40,386,000. 89.70% of the stock is owned by institutional investors.

In other Chemed news, VP Michael D. Witzeman sold 1,706 shares of the business’s stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $322.00, for a total value of $549,332.00. Following the transaction, the vice president now owns 4,000 shares in the company, valued at $1,288,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $319.50, for a total transaction of $1,278,000.00. Following the completion of the transaction, the insider now owns 139,491 shares in the company, valued at approximately $44,567,374.50. The disclosure for this sale can be found here. Insiders sold 6,006 shares of company stock worth $1,923,098 in the last 90 days. Corporate insiders own 4.82% of the company’s stock.

A number of brokerages recently commented on CHE. ValuEngine cut shares of Chemed from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $350.00 price objective on the stock in a research report on Tuesday, July 31st. Bank of America started coverage on shares of Chemed in a research report on Friday, October 12th. They issued a “buy” rating and a $390.00 price objective on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of Chemed to $321.00 and gave the company a “market perform” rating in a research report on Monday, July 30th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Chemed presently has an average rating of “Buy” and a consensus target price of $334.00.

CHE stock opened at $300.11 on Tuesday. Chemed Co. has a 12-month low of $206.80 and a 12-month high of $335.99. The stock has a market capitalization of $4.86 billion, a price-to-earnings ratio of 29.00, a PEG ratio of 2.71 and a beta of 1.17. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.01 and a current ratio of 1.04.

Chemed (NYSE:CHE) last released its quarterly earnings data on Wednesday, July 25th. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. Chemed had a net margin of 11.00% and a return on equity of 33.57%. The firm had revenue of $441.80 million for the quarter, compared to analysts’ expectations of $434.28 million. During the same quarter in the previous year, the company earned $2.15 earnings per share. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, equities analysts predict that Chemed Co. will post 11.14 EPS for the current year.

Chemed Company Profile

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Further Reading: How to Invest in an Index Fund

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.